MedTrace Logo

Dead Mesenchymal Stem Cells for Radiation Lung Injury

NCT06021067 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-09-01

No results posted yet for this study

Summary

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of hDMSCs in the treatment of radiation pneumonitis.

Conditions

  • Radiation Lung Injury

Interventions

BIOLOGICAL

Death mesenchymal stem cell

A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks.

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Zhen-Yu Ding, Prof · Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-10
Primary Completion
2024-09-10
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06021067 on ClinicalTrials.gov